The NCMAG Council makes decisions on the proposed use of cancer medicines.
These medicines uses are planned for review by NCMAG:
NCMAG 129 Aspirin
Adjuvant treatment of patients with resected stage I to III rectal cancer or stage II to III colon cancer and PI3K pathway alterations (off-label and off-patent medicine).
- Council meeting date: 17 September 2026
- Planned publication date: 22 October 2026